Home » Newsletters » BioWorld Science

BioWorld Science

July 22, 2008

View Archived Issues

Repros reports results from two studies of Proellex

Novel cancer therapeutics described in recent patent literature

MMRC initiates phase I/II study of elotuzumab in combination with Velcade

AGI presents an update on the ARDIS phase III program for Rezular in IBS-D

Lilly pays Galapagos EUR 1 million milestone payment under osteoporosis collaboration

Neuren completes recruitment and dosing in phase III trial of Glypromate

sanofi-aventis terminates development and commercialization agreement with Taiho for S-1

Biocon and Abraxis launch Abraxane in India for breast cancer

New treatment option for HIV infection disclosed in recent Genzyme patent

Recent Merck patent divulges new agents for bone disorders

Genentech reports on preclinical profile of MetMAb in pancreatic cancer models

Allos initiates phase II PDX study in transitional cell carcinoma of the bladder

Ambrilia starts phase I/II program of novel goserelin formulation in prostate cancer

BioCancell requests to begin phase I BC-819 trial in pancreatic cancer

Intranasal administration of testosterone shows benefit against depressive-like behavior

Curis selects Hsp90 inhibitor CUDC-305 as development candidate

MI-63 plus cisplatin effective combination against cisplatin-resistant head and neck cancer

Exelixis commences phase III XL-184 trial in medullary thyroid cancer

Vascular disrupting agent ASA-404 shows benefit in mouse model of head and neck cancer

Roche offers to acquire all outstanding shares of Genentech

Targacept begins phase IIb TC-5214 trial in major depressive disorder

AlphaVax initiates studies of prototype chlamydia vaccine

CSL Behring submits BLA to FDA for human fibrinogen concentrate for congenital bleeding

BMP Sunstone signs letter of intent to acquire Shengda for approximately USD 4.4 million

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
News in brief
BioWorld Asia
BioWorld Asia briefs for Feb. 10, 2026